Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Single-Arm Clinical Trial to Evaluate the Immunogenicity and Safety of a Booster Dose of an Adjuvanted Recombinant Spike Protein COVID-19 Vaccine (SpikoGen) in Kidney Transplant Recipients After Two Doses of Sinopharm COVID-19 Vaccine

NCT05285384 is registered in ClinicalTrials.gov with Cinnagen as lead sponsor.

NCT NCT05285384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05285384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Single-Arm Clinical Trial to Evaluate the Immunogenicity and Safety of a Booster Dose of an Adjuvanted Recombinant Spike Protein COVID-19 Vaccine (SpikoGen) in Kidney Transplant Recipients After Two Doses of Sinopharm COVID-19 Vaccine
Lead sponsor
Cinnagen
Phase
Not applicable
Overall status
Completed
Start date
February 4, 2022
Completion date
March 30, 2022
Enrollment
43 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19